Australian pharmaceuticals heavyweight CSL says its chief executive Paul McKenzie is leaving the company with immediate ...

One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. | One day after CSL revealed that it had suddenly replaced its CEO, the company ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the ...

The global biotechnology firm’s shares plunged 12pc when the market opened, with analysts concerned it will not meet full-year guidance.

The most recent earnings report from CSL Limited (ASX:CSL) was disappointing for shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income ...

Shares of biotech company CSL plunged after the company announced that Chief Executive Officer Paul McKenzie will step down.

CSL has maintained full-year guidance of 2 to 3 percent revenue growth and 4 to 7 percent NPATA growth, excluding ...

CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies.  | The deal allows CSL to ...

Workers at biotech giant CSL will strike for 24 hours on Wednesday after accusing the company of threatening to extend their working hours, cut conditions and move office-based employees off an ...

A toxic mix of Americans turning away from vaccines, collapsing blood plasma sales in China and a billion-dollar impairment ...

CSL Ltd on Wednesday reported an 81% drop in first‑half profit, knocked by weaker blood plasma product and vaccine sales and one-off charges, a day after CEO Paul McKenzie stepped down, sending ...

Strong revenue growth continues for CSL. Its debt is well in hand, share buybacks are a plus, and dividends remain stable and payable. The big problem here is the potential future for the Construction ...